In vitro activity of tigecycline (GAR-936) and other antimicrobials against tetracycline- and ciprofloxacin-resistant Campylobacter clinical isolates.
During 2003 in our hospital, 236 clinical faecal Campylobacter spp. were isolated, of which 166 (70%) were resistant to tetracycline and 199 (84%) were resistant to ciprofloxacin by the disk diffusion method. Resistance to both antimicrobial agents was found in 146 isolates (62%). The in vitro activity of tigecycline was compared with that of erythromycin, clindamycin and amoxicillin/clavulanic acid using the agar dilution method against 116 selected Campylobacter spp. that were resistant to both tetracycline and ciprofloxacin. The minimum inhibitory concentration at which 90% of the isolates were inhibited (MIC90) was 0.06 mg/L for tigecycline and 4, 2 and 1 microg/mL for amoxicillin/clavulanic acid, erythromycin and clindamycin, respectively. The high in vitro activity of tigecycline against tetracycline- and ciprofloxacin-resistant strains suggests a potential therapeutic role in the treatment of infections that involve Campylobacter spp.
Servicio de Microbiología, Hospital Clínico San Carlos, Plaza de Cristo Rey s/n, 28040 Madrid, Spain. iciaravial@hotmail.com
Iciar
I
Rodríguez-Avial
Carmen
C
Rodríguez-Avial
Olga
O
López
Esther
E
Culebras
Juan J
JJ
Picazo
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D002167:Campylobacter / Q000187:drug effects* / Q000302:isolation & purification; D002169:Campylobacter Infections / Q000382:microbiology; D002939:Ciprofloxacin / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D024901:Drug Resistance, Multiple, Bacterial; D005243:Feces / Q000382:microbiology; D006761:Hospitals; D006801:Humans; D007297:Inpatients; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology; D013030:Spain; D013753:Tetracycline Resistance; D000078304:Tigecycline
D000900:Anti-Bacterial Agents; D002939:Ciprofloxacin; D000078304:Tigecycline; D008911:Minocycline